Table 3.
Model1 | Model2 | Model3 | |
---|---|---|---|
HR (95%CI) | HR (95%CI) | HR (95%CI) | |
CAR | 2.90 (2.40–3.49) | 2.85 (2.36–3.45) | 1.94 (1.56–2.41) |
GPS | |||
1 | 1.93 (1.40–2.65) | 1.81 (1.32–2.50) | 1.36 (0.97–1.88) |
2 | 3.24 (2.36–4.45) | 2.99 (2.19–4.11) | 1.91 (1.36–2.67) |
mGPS | |||
1 | 0.97 (0.56–1.70) | 1.02 (0.58–1.78) | 1.15 (0.65–2.05) |
2 | 1.99 (1.65–2.40) | 1.91 (1.59–2.31) | 1.50 (1.23–1.83) |
hs-mGPS | |||
1 | 2.24 (1.40–3.58) | 2.19 (1.37–3.50) | 1.79 (1.11–2.87) |
2 | 3.99 (2.59–6.14) | 3.71 (2.40–5.71) | 2.30 (1.47–3.59) |
In bold significant associations
Model 1: unadjusted
Model 2: adjusted for age, gender
Model 3: adjusted for age, gender, use of 5 + Drugs, 3 + lost ADL, 3 + lost IADL, eGFR, NLR, ALT, Hgb, Platelet, AMI, liver cirrhosis, CHF, CeVD, dementia, COPD, Parkinson, hypertension, CKD, diabetes, sepsis, cancer